<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00910754</url>
  </required_header>
  <id_info>
    <org_study_id>CR016942</org_study_id>
    <secondary_id>COU-AA-006</secondary_id>
    <nct_id>NCT00910754</nct_id>
  </id_info>
  <brief_title>A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>A QT/QTc and Multi-dose PK Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration- Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of abiraterone acetate plus prednisone
      on the conduction of electric charges within the heart and to determine the blood levels of
      abiraterone acetate following administration in patients with metastatic castration-resistant
      prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (identity of assigned study drugs will be known) study to evaluate the
      effects of abiraterone acetate plus prednisone on the conduction of electric charges within
      the heart in male patients diagnosed with metastatic castration-resistant prostate cancer (a
      progressive form of prostate cancer that spreads to other parts of the body). At various time
      points outline in the protocol from Day -1 of Cycle 1 up to Day 2 of Cycle 2, patients will
      have electrocardiograms extracted from a 24 hour holter-monitor to evaluate the electrical
      activity of their heart. Efficacy will be assessed according to Prostate Cancer Working Group
      2 and modified Response Evaluation Criteria In Solid Tumors criteria. Serial blood samples
      for pharmacokinetic analysis (how the drug concentrations change over time) will be collected
      and safety will be monitored throughout the study. Patients will take 1000 mg of abiraterone
      acetate once daily plus prednisone 5 mg twice daily orally (by mouth) until disease
      progression and will be followed up for up to 60 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean maximal change in electrocardiogram QTc</measure>
    <time_frame>Baseline on Day -1 of Cycle 1 compared with Day 1 of Cycle 1, Cycle 2, Cycle 4 and every third cycle thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with change from baseline electrocardiogram QTc &gt;30 msec</measure>
    <time_frame>Pre-dose Cycles 1, 2, 4, and every third cycle after Cycle 4, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose, and end of study visit (4 weeks after last dose of study drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with change from baseline electrocardiogram QTc &gt;60 msec</measure>
    <time_frame>Pre-dose Cycles 1, 2, 4, and every third cycle after Cycle 4, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose, and end of study visit (4 weeks after last dose of study drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants affected by an adverse event</measure>
    <time_frame>Up to 30 days after the last dose of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with change in cortrosyn stimulation test</measure>
    <time_frame>Baseline and end of study visit (4 weeks after last dose of study drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with change in serum blood levels of testosterone</measure>
    <time_frame>Baseline and end of study visit (4 weeks after last dose of study drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with change in adrenocorticotropic hormone</measure>
    <time_frame>Baseline and end of study visit (4 weeks after last dose of study drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean plasma concentrations of abiraterone</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentrations of abiraterone</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum plasma concentration of abiraterone</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma-concentration-time curve from time 0 to the last quantifiable concentration of abiraterone</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma-concentration-time curve from time 0 to infinite time of abiraterone</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life of abiraterone</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression free survival</measure>
    <time_frame>Up to Month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to Month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with prostate specific antigen response</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to prostate specific antigen progression according to Prostate Cancer Working Group 2 criteria</measure>
    <time_frame>Up to Month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with objective radiographic response according to Prostate Cancer Working Group 2 criteria</measure>
    <time_frame>Up to Month 60</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Prostate Neoplasms</condition>
  <arm_group>
    <arm_group_label>Abiraterone acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take 1000 mg of abiraterone acetate once daily plus prednisone 5 mg twice daily orally (by mouth) until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone acetate</intervention_name>
    <description>Abiraterone acetate 1000 mg (4 x 250 mg tablets) administered orally once daily.</description>
    <arm_group_label>Abiraterone acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 5 mg tablets administered orally twice daily.</description>
    <arm_group_label>Abiraterone acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate without
             neuroendocrine differentiation or small cell histology

          -  Documented metastatic disease

          -  Has not received chemotherapy or has no more than one line of cytotoxic chemotherapy
             or biologic therapy for treatment of castration resistant prostate cancer (CRPC)

          -  Documented prostate specific antigen (PSA) progression as assessed by the investigator
             according to Prostate Cancer Working Group 2 (PCWG2) criteria despite medical or
             surgical castration, or prostate cancer progression documented by radiographic
             progression according to Response Evaluation Criteria In Solid Tumors (RECIST)
             criteria

          -  Surgically or medically castrated with testosterone levels of &lt;50 ng/dL (&lt;2.0 nM)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of &lt;= 1

          -  Agrees to protocol-defined use of effective contraception

          -  Protocol-specified laboratory parameters

        Exclusion Criteria:

          -  Serious or uncontrolled co-existent non-malignant disease, including active and
             uncontrolled infection

          -  Abnormal liver function

          -  Uncontrolled hypertension

          -  Active or symptomatic viral hepatitis or chronic liver disease

          -  Known brain metastasis

          -  History of pituitary or adrenal dysfunction

          -  Clinically significant heart disease as evidenced by myocardial infarction, or
             arterial thrombotic events in the past 6 months, severe or unstable angina, or New
             York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction
             measurement of &lt; 50 % at baseline

          -  Diagnosis of cardiac arrhythmia

          -  Treatment with anti-arrhythmic drugs primarily for cardiac arrhythmia

          -  Abnormal electrocardiogram

          -  Other malignancy (except non-melanoma skin cancer, that is active or has a â‰¥ 30%
             probability of recurrence within 24 months) History of gastrointestinal disorders
             (medical disorders or extensive surgery) which may interfere with the absorption of
             the study drug

          -  Surgery or local prostatic intervention within 30 days of the first dose

          -  Radiotherapy or immunotherapy within 30 days, or single fraction of palliative
             radiotherapy within 14 days of administration of Cycle 1 Day 1

          -  Any acute toxicities due to prior therapy that have not resolved to a NCI CTCAE
             (version 3.0) grade of &lt;=1

          -  More than one prior cytotoxic chemotherapy or biologic therapy for treatment of CRPC

          -  Prior chemotherapy with mitoxantrone or other anthracyclines (ie, doxorubicin,
             daunomycin, epirubicin and idarubicin)

          -  Current enrollment in an investigational drug or device study or participation in such
             a study within 30 days of Cycle 1 Day 1

          -  Prior flutamide (Eulexin) treatment within 4 weeks of Cycle 1 Day 1

          -  Prior bicalutamide (Casodex), nilutamide (Nilandron, Anandron) within 6 weeks of Cycle
             1 Day 1

          -  Previous abiraterone acetate or other investigational CYP17 inhibitor (eg, TAK-700)

          -  Previous investigational antiandrogens (eg, MDV3100, BMS-641988)

          -  Patients receiving anti-coagulant therapy

          -  Condition or situation which, in the investigator's opinion, may put the patient at
             significant risk, may confound the study results, or may interfere significantly with
             patient's participation in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency-Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=2396&amp;filename=CR016942_CSR.pdf</url>
    <description>A QT/QTc and Multi-dose PK Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration- Resistant Prostate Cancer</description>
  </link>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2009</study_first_submitted>
  <study_first_submitted_qc>May 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2009</study_first_posted>
  <last_update_submitted>April 11, 2013</last_update_submitted>
  <last_update_submitted_qc>April 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate neoplasms</keyword>
  <keyword>Metastatic castration resistant prostate cancer</keyword>
  <keyword>Abiraterone acetate</keyword>
  <keyword>CB7630</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

